Tourette syndrome associated with mental retardation: a single-subject treatment study with haloperidol.
A Tic Checklist and direct observation tic measurement procedure were developed for the assessment of Tourette syndrome in individuals with mental retardation. Using a single-subject reversal design, we applied this assessment method to the evaluation of haloperidol treatment for a subject with Tourette syndrome and severe mental retardation. Relative to baseline, haloperidol 10 mg/day produced decreases of 66% in simple motor tics, 46% in complex motor tics, 45% in simple vocal tics, and 50% in complex vocal tics. Improvement was also seen in careprovider ratings of tic severity, hyperactivity, and compulsive behaviors.
Rosenquist
P B
PB
Bowman Gray School of Medicine Winston-Salem, NC, USA.
Bodfish
J W
JW
Thompson
R
R
D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008607:Intellectual Disability / Q000150:complications*; D008137:Longitudinal Studies; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D005879:Tourette Syndrome / Q000150:complications / Q000188:drug therapy*
D018726:Anti-Dyskinesia Agents; D006220:Haloperidol